Lantheus | Sustainability Performance
Develops diagnostic imaging agents and therapeutic products used in healthcare. Its portfolio includes contrast agents for medical imaging, as well as radiopharmaceuticals for targeted applications. The company supports clinicians through technologies designed to enhance diagnostic accuracy and patient management.
1956
United States
501 - 1,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#8570
Overallⓘ#1977
in United Statesⓘ#203
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Lantheus Holdings Inc, US radiopharmaceuticals, has faced multiple US class actions over alleged inadequate disclosure of Pylarify PSMA PET imaging customer demand changes affecting share price, plus periodic US FDA enforcement scrutiny at multiple Lantheus production facilities affecting product quality compliance amid US PSMA PET market normalization.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
4-6
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.